FindTrial
Sign In

A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)

A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001043-30-IT
Enrollment
Unknown
Registered
2005-03-07
Start date
2004-10-25
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC) MedDRA version: 6.1 Level: PT Classification code 10026532

Interventions

Product Name: gimatecan Product Code: ST1481 Pharmaceutical Form: INN or Proposed INN: gimatecan Current Sponsor code: ST1481 Concentration unit: mg milligram(s) Concentration type: equal Concentrati

Sponsors

SIGMA-TAU
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026